+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
ID07725601

Comparing Rapid and Standard Programming of Vagus Nerve Stimulator in Adults with Epilepsy to Assess Seizure Reduction

Led by Fernando Vale · Updated on 2026-07-24

80

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new rapid programming method for the Vagus Nerve Stimulator VNS device compared to the standard programming in adults with drug-resistant epilepsy. The goal is to determine if the modified programming, called the Augusta Way, can reduce seizures faster than the standard approach. This study addresses the lack of recent updates in VNS therapy programming and aims to provide a comprehensive dosing protocol for improved treatment escalation. Participants are assigned to either the experimental group receiving the rapid titration VNS programming or the control group receiving standard VNS programming. Both groups will be followed for at least 24 months after device implantation to assess safety and effectiveness based on seizure outcomes. The study uses a parallel design without masking and involves regular follow-up visits. During the 2-year participation, participants will attend up to three study visits every three months. They will complete questionnaires assessing quality of life and cognitive function while maintaining a diary to record seizure activity. Researchers will monitor seizure frequency from enrollment through the entire study period to evaluate the impact of the programming methods on seizure control.

CONDITIONS

Brief Title

VNS Algorithm for Advanced Dosing

Research Team

B

Brandy Quarles, MPH

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here